1. Introduction

Biotechnology Autonomous Research Systems (BARS) refers to advanced research technologies capable of conducting scientific experiments, analysing biological data, selecting experimental procedures, operating laboratory equipment and generating scientific conclusions with limited or no continuous human intervention.

Examples include:

AI-powered laboratories conducting autonomous biological experiments.

Robotic systems performing genetic sequencing and molecular analysis.

Automated CRISPR gene-editing research platforms.

AI systems identifying new pharmaceutical compounds.

Autonomous cell-culture and synthetic-biology laboratories.

Machine-learning systems designing proteins and predicting biological interactions.

Robotic laboratories conducting microbiological and genomic research.

In Russia, autonomous biotechnology research is governed by several overlapping legal frameworks involving scientific research, genetic engineering, biological safety, personal data, medical products, intellectual property and civil liability.

Important legal distinction: Russia does not have one comprehensive statute specifically entitled Autonomous Biotechnology Research Systems Law. Instead, the legality of these systems must be assessed under existing Russian legislation and applicable technical and regulatory requirements.

2. Main legislative framework in Russia

A. Federal Law No. 86-FZ of 5 July 1996 – State Regulation of Genetic Engineering Activities

The principal legislation governing genetic-engineering activities is Federal Law No. 86-FZ.

It is particularly relevant when autonomous research systems conduct experiments involving genetically modified organisms (GMOs), recombinant DNA, genetic manipulation or biological materials.

Its principal objectives include:

Protecting human health during genetic-engineering activities.

Preventing environmental damage caused by genetically modified organisms.

Regulating the creation and use of genetically engineered organisms.

Establishing safety requirements for biotechnology products.

Regulating the handling and transfer of genetic information.

Providing a framework for government supervision.

Article 1 – Scope of application

The legislation regulates genetic-engineering activities in relation to environmental protection, ecological safety and human health.

Article 4 – Regulatory objectives

The law establishes the objectives of state regulation, including protection of citizens and the environment and the development of genetic-engineering technologies.

Article 6 – Genetic-engineering activities

The provision covers genetic manipulations at molecular and cellular levels, including activities involving recombinant nucleic acids and genetically modified organisms.

Article 11 – Certification and conformity

Products and services obtained through genetic-engineering methods must satisfy applicable environmental, sanitary, pharmacopoeial and other mandatory legal requirements.

These provisions mean that an autonomous laboratory cannot avoid biotechnology regulation merely because an AI system or robot performs the experiment instead of a human researcher.

ГАРАНТ+3

Important 2026 amendment: Federal Law No. 43-FZ of 20 February 2026 amended Law No. 86-FZ. Its relevant amendments entered into force on 1 September 2026. They expressly address human genetic data and its transfer, strengthening the legal framework for research systems processing genetic information.

CIS Legislation+2

B. Federal Law No. 492-FZ of 30 December 2020 – Biological Safety

This law establishes the national framework for protecting people, animals, plants and the environment against dangerous biological factors.

It is especially important for autonomous biotechnology laboratories because automated systems may independently handle microorganisms, biological samples and potentially hazardous materials.

Important provisions include:

Article 3: Principles of biological safety.

Article 7: Rights and obligations of organisations operating in the biological-safety field.

Article 8: Principal biological threats and dangers.

Article 9: Measures for protecting people and the environment.

Article 11: Collection-related activities involving pathogenic microorganisms and viruses.

Article 12: Prevention of accidents, sabotage and uncontrolled dangerous biological activities.

Article 13: Biological-risk monitoring.

Article 16: Liability for violations of biological-safety legislation.

Application to autonomous laboratories

A biotechnology institution using autonomous robotic equipment should establish:

Biological-risk assessment procedures.

Restricted access to hazardous biological materials.

Emergency shutdown mechanisms.

Human supervision of high-risk experiments.

Secure storage and traceability of biological samples.

Incident reporting and investigation systems.

An autonomous system's unexpected experimental decision does not remove the organisation's responsibility to maintain biological safety.

Consultant Plus+1

C. Federal Law No. 152-FZ of 27 July 2006 – Personal Data

Autonomous biotechnology research systems frequently process:

Human DNA sequences.

Genomic profiles.

Medical histories.

Genetic predisposition information.

Biological sample identifiers.

Research-participant information.

The Personal Data Law is therefore relevant to research institutions processing identifiable human biological information.

Important provisions:

Article 5: Principles and limitations of personal-data processing.

Article 6: Legal grounds for processing.

Article 9: Consent to processing.

Article 10: Special categories of personal data.

Article 18: Requirements concerning personal-data processing and localisation.

Article 19: Security measures.

Research institutions must establish appropriate legal grounds for processing, protect identifiable information and prevent unauthorised disclosure.

A system that automatically transfers genomic information to an external cloud provider may create additional data-protection and cross-border-transfer issues.

D. Federal Law No. 323-FZ of 21 November 2011 – Protection of Citizens' Health

This law becomes relevant when autonomous research systems are used for biomedical research, clinical investigations, experimental treatments or medical technologies.

Relevant provisions include:

Article 20: Informed voluntary consent to medical intervention.

Article 37: Organisation and provision of medical care.

Article 38: Medical devices.

Article 40: Medical rehabilitation.

Article 47: Donation of organs and tissues.

Article 75: Medical risks and their assessment.

An AI-controlled research platform cannot independently replace legally required consent from a research participant or patient.

Where an autonomous system produces findings intended for clinical use, the applicable medical research, medical-device and clinical-safety requirements must also be considered.

E. Federal Law No. 258-FZ of 31 July 2020 – Experimental Legal Regimes

This law provides a framework for experimental legal regimes involving digital and technological innovations.

It is relevant to biotechnology research platforms incorporating:

Artificial intelligence.

Robotic laboratory operations.

Automated scientific experimentation.

Digital biological modelling.

Innovative research-management systems.

An experimental legal regime may permit specified innovations to operate under specially approved conditions and regulatory supervision.

However, participation in an experimental regime does not automatically exempt a laboratory from biological-safety, personal-data or other mandatory requirements.

3. Legal status of autonomous biotechnology research systems

A central question is whether an autonomous laboratory or AI research system can independently possess legal rights and obligations.

Under the ordinary framework of Russian civil law, an AI system is not independently recognised as a natural person or legal entity.

Consequently, an autonomous biotechnology system cannot independently:

Obtain legal personality merely by conducting experiments.

Enter into contracts in its own legal capacity.

Assume independent civil liability.

Hold legal responsibility for regulatory violations.

Replace the legally responsible research organisation.

The relevant legal responsibility generally remains with the natural persons and legal entities involved.

Potential responsible parties

The exact allocation depends on the conduct, contractual arrangements, statutory duties and causal connection between the conduct and the harm.

4. Regulation of autonomous scientific decision-making

Autonomous research systems may make experimental decisions without receiving continuous instructions from researchers.

For example, an AI platform may:

Analyse biological samples.

Identify a genetic sequence.

Select a proposed experimental method.

Operate laboratory equipment.

Evaluate the experimental results.

Recommend additional experiments.

Generate a scientific report.

Russian law does not create a general exemption for these activities simply because they are automated.

The following legal principles are particularly important.

A. Human accountability

The institution must maintain identifiable human responsibility for research decisions, safety procedures and regulatory compliance.

B. Scientific reliability

Research results should be reproducible, appropriately validated and supported by reliable experimental records.

C. Algorithmic transparency

The institution should maintain sufficient documentation concerning the AI model, experimental inputs, system updates and decision-making process.

D. Safety and risk prevention

Autonomous systems should have suitable access restrictions, operational controls and emergency procedures.

E. Traceability

The institution should preserve records of experimental decisions, biological materials, equipment operations and system interventions.

These are compliance measures derived from the applicable legal duties; they should not be mistaken for a single statutory AI-laboratory certification scheme.

5. Artificial Intelligence Law No. 243-FZ of 26 July 2026

A significant recent development is Russia's Federal Law No. 243-FZ, On Supporting the Development of Artificial Intelligence Technologies in the Russian Federation.

It entered into force on 1 September 2026, although certain provisions, including Articles 8–10, have a later commencement date of 1 March 2027.

The law primarily concerns large fundamental AI models rather than autonomous biotechnology laboratories as a separate category.

Important provisions include:

Significance for biotechnology

An autonomous biotechnology platform using a covered AI model may be affected by requirements relating to the development, deployment and use of that model.

For example, a Russian biotechnology company using AI to develop pharmaceutical compounds must consider the applicable AI framework alongside pharmaceutical, genetic-engineering and intellectual-property legislation.

However, Law No. 243-FZ should not be interpreted as granting autonomous research systems independent legal personality.

Consultant Plus+2

6. Important case laws and judicial precedents

There is an important limitation in Russian biotechnology jurisprudence: publicly identifiable reported decisions specifically addressing liability for autonomous biotechnology research systems are extremely limited. The following decisions and precedents therefore need to be distinguished between direct biotechnology cases and legally relevant analogies.

Case 1. Arbitrazh Court of the West Siberian District – Case No. A27-7831/2025 (14 May 2026)

AI-related judicial precedent

Legal issue: Responsibility for inaccurate AI-assisted legal submissions.

The case concerned a company that submitted fabricated or misrepresented judicial authorities in court proceedings.

The court imposed a RUB 50,000 fine for contempt after finding that false information had been submitted in a manner capable of misleading the court.

Legal principles:

A party remains responsible for the accuracy of its court submissions.

Reliance on AI does not automatically excuse inaccurate information.

Human or corporate responsibility cannot simply be transferred to an AI tool.

AI-generated material must be independently verified.

Relevance to biotechnology

If an autonomous research platform produces fabricated scientific references, inaccurate experimental records or misleading research conclusions, the responsible research institution cannot automatically avoid accountability by blaming its AI system.

This is an analogy concerning responsibility for AI-assisted conduct, not a biotechnology judgment.

Oxford Institute of Technology and Justice

Case 2. Rostov Regional Court – Case No. 22-5597/2025 (20 November 2025)

AI-generated evidence

Legal issue: Evidentiary reliability of AI-generated medical analysis.

In this criminal proceeding, the defendant submitted an AI-generated analysis of a photograph of an injury to challenge the prosecution's medical findings.

The court did not consider the AI-generated opinion sufficiently substantiated to give it evidentiary weight.

Legal principles:

AI-generated conclusions are not automatically reliable evidence.

Technical analysis must be supported by appropriate verification.

The evidentiary value of a scientific conclusion depends on its reliability and supporting material.

Human adjudicators retain responsibility for evaluating evidence.

Relevance to biotechnology

Suppose an autonomous laboratory generates a DNA-analysis report or identifies a genetic mutation. A court should not treat the computer-generated conclusion as scientifically conclusive merely because sophisticated AI technology produced it.

Independent validation, laboratory records, expert evidence and appropriate chain-of-custody documentation may be essential.

This is an evidentiary analogy rather than a case concerning autonomous laboratories.

Oxford Institute of Technology and Justice

Case 3. EPO Technical Board of Appeal – DABUS, Case J 8/20 (21 December 2021)

International comparative precedent

Legal issue: Whether an autonomous AI system can be recognised as an inventor.

The DABUS system was presented as having independently generated inventions for which patent protection was sought.

The European Patent Office maintained that the designated inventor must be a natural person.

Legal principles:

An AI system cannot automatically be treated as a legally recognised human inventor.

Patent inventorship and ownership must be distinguished.

Human involvement in developing or operating an AI system does not automatically establish inventorship.

Patent law must identify the legally recognised inventor.

Relevance to Russia

The decision is not binding on Russian courts. Nevertheless, it provides a useful comparative framework for autonomous biotechnology research.

For example, if an AI system independently designs a new protein, pharmaceutical compound or genetic-engineering technique, questions arise concerning the identification of the inventor and ownership of resulting intellectual-property rights.

Russian patent law must be examined independently, particularly the Civil Code provisions governing inventions and inventorship.

WIPO+1

Case 4. Russian GMO regulatory judicial practice

The US Library of Congress published a legal analysis of Russian GMO regulation identifying Federal Law No. 86-FZ and associated environmental, sanitary and consumer-protection requirements.

Its historical review reported that Russia had no significant judicial decisions shaping GMO regulatory enforcement at the time of publication.

Although that review dates from 2015 and cannot establish the position in 2026, it illustrates the historically limited development of reported GMO case law.

Accordingly, it would be misleading to invent Russian court judgments specifically concerning autonomous genetic-engineering laboratories.

Law Library of Congress

7. Civil liability for autonomous biotechnology research

Russian civil liability is particularly important when an autonomous laboratory causes damage.

The Civil Code of the Russian Federation provides the general legal framework.

Article 15 – Compensation for losses

A person whose rights have been violated may seek compensation for legally recoverable losses.

Article 1064 – General grounds of liability for causing harm

This provision establishes the general obligation to compensate harm caused to another person or property, subject to the applicable legal conditions and defences.

Article 1079 – Liability for activities involving increased danger

Depending on the circumstances, the operation of dangerous laboratory equipment or other activities presenting an increased danger may fall within the rules on liability for sources of increased danger.

Article 1228 – Author of the result of intellectual activity

This provision is relevant when determining authorship of intellectual-property results. An AI system itself does not become a human author merely by generating a scientific output.

Practical example

Suppose an autonomous biotechnology laboratory conducts genetic-engineering experiments and a malfunction causes the accidental release of a harmful microorganism.

Potential legal consequences may include:

Compensation for personal injury.

Environmental damage claims.

Administrative penalties.

Regulatory investigations.

Suspension of laboratory operations.

Criminal proceedings where the statutory elements of an offence are established.

The responsible party will depend on the particular facts, including the laboratory's safety arrangements, operator conduct, equipment defects and causal connection to the harm.

8. Intellectual property rights in autonomous biotechnology research

Autonomous research systems can generate commercially valuable discoveries.

Examples include:

New protein structures.

Novel pharmaceutical compounds.

Genetic-engineering techniques.

Biological manufacturing processes.

Artificially designed microorganisms.

New diagnostic methods.

The principal legal framework is Part IV of the Russian Civil Code.

Important provisions include:

An important distinction must be maintained between the AI system's contribution and the legal rights of the human researchers, employers and other relevant rights holders.

For example, where a researcher uses an autonomous platform to identify a new therapeutic protein, patent entitlement must be assessed under the applicable inventorship and ownership rules.

The AI system's computational contribution does not itself establish independent patent ownership.

9. Ethical and scientific accountability

Autonomous biotechnology research creates ethical problems that traditional laboratory regulations may not fully address.

A. Human research participants

Research involving human biological samples should respect informed consent, confidentiality and applicable medical-research requirements.

B. Genetic discrimination

Genetic information should not be used unlawfully to discriminate against research participants or individuals.

C. Experimental manipulation

Autonomous systems must operate within applicable legal restrictions governing genetic manipulation and biological materials.

D. Scientific misconduct

Research institutions should investigate fabricated data, manipulated experimental results and inaccurate AI-generated scientific publications.

E. Dual-use biotechnology

Some biological research can have both beneficial and potentially harmful applications. Institutions should evaluate the risks of research involving dangerous pathogens and potentially harmful biological technologies.

Russia's Federal Law No. 492-FZ provides an important statutory foundation for biological-risk prevention and monitoring.

Consultant Plus+2

10. Administrative and criminal liability

Violations involving autonomous biotechnology systems can lead to different forms of legal responsibility.

The Criminal Code may become relevant depending on the offence and the facts.

Potentially relevant provisions include:

Article 109: Causing death by negligence.

Article 118: Causing serious or moderately serious harm to health by negligence.

Article 236: Violation of sanitary and epidemiological rules.

Article 246: Violation of environmental-protection rules during work.

Article 247: Violation of rules governing hazardous substances and waste.

These provisions do not automatically apply whenever an autonomous research system malfunctions. The statutory elements, causation and applicable mental element must be established.

11. Institutional compliance requirements for autonomous biotechnology laboratories

A Russian biotechnology institution planning to introduce autonomous research systems should establish an appropriate compliance framework.

Recommended institutional compliance checklist

Regulatory authorisation

Identify applicable research permissions, registrations and licensing requirements.

Biological safety

Conduct biological-risk assessments and establish containment procedures.

Human supervision

Assign qualified personnel to supervise high-risk autonomous experiments.

AI validation

Validate the system's scientific accuracy and operational reliability.

Audit trails

Preserve experimental records, algorithmic decisions and equipment logs.

Genetic-data protection

Establish lawful processing, access restrictions and appropriate security measures.

Intellectual property

Identify human inventors, ownership rights and research agreements.

Incident response

Establish emergency shutdown, reporting and investigation procedures.

Independent review

Conduct periodic scientific, ethical and regulatory audits.

12. Major legal challenges

The following unresolved or developing issues are particularly important:

Autonomous decision-making: Determining the appropriate level of human oversight when AI independently selects experimental procedures.

Algorithmic accountability: Establishing responsibility when an autonomous research system produces harmful scientific decisions.

Biological safety: Preventing automated systems from conducting dangerous experiments without appropriate safeguards.

AI inventorship: Determining the human inventors and ownership of AI-generated biotechnology inventions.

Genetic-data protection: Protecting human genomic information processed by autonomous platforms.

Scientific evidence: Establishing standards for the admissibility and reliability of AI-generated biological findings.

International research: Addressing cross-border transfers of biological materials and genetic information.

Regulatory coordination: Coordinating AI, biotechnology, environmental and medical regulators.

13. Important legislation and legal authorities: consolidated table

14. Conclusion

Biotechnology Autonomous Research Systems Law in Russia is an emerging area at the intersection of artificial intelligence, genetic engineering, biological safety, medical research and civil liability.

The central statutory foundation remains Federal Law No. 86-FZ of 1996, supplemented by Federal Law No. 492-FZ of 2020 and other applicable legislation.

The 2026 amendments are particularly significant because they develop the legal framework for human genetic data and introduce a dedicated federal framework for certain large AI models.

Three fundamental legal principles emerge:

Human accountability: Autonomous research systems do not independently replace the legal responsibility of researchers and institutions.

Biological safety: Automation does not eliminate regulatory obligations concerning dangerous biological materials and genetic-engineering activities.

Scientific and intellectual-property accountability: AI-generated discoveries and scientific conclusions must be assessed under applicable evidentiary, patent and civil-law principles.

Ultimately, Russia's existing legislation provides several mechanisms for regulating autonomous biotechnology research, but specific statutory rules governing autonomous laboratory decision-making, AI inventorship and responsibility for autonomous biological experimentation remain important areas for future legal development.

15. References for further legal research

The following sources are useful for examining the legislation and relevant judicial developments:

Federal Law No. 86-FZ – Genetic Engineering Activities.

Federal Law No. 492-FZ – Biological Safety.

Federal Law No. 243-FZ – Artificial Intelligence, 2026.

Federal Law No. 258-FZ – Experimental Legal Regimes.

Federal Law No. 43-FZ – Genetic-Data Amendments, 2026.

WIPO – DABUS and AI Inventorship.

Library of Congress – Russian GMO Regulation.

Research qualification: The cases discussed above are relevant analogies, not a collection of binding Russian judgments specifically regulating autonomous biotechnology laboratories. This distinction is important when preparing an academic dissertation, legal article or case-law-based research paper.